Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes

Appetecchia, Marialuisa

Bianchi, Antonio

Chiloiro, Sabrina

Costa, Denise

De Marinis, Laura

Gargiulo, Patrizia

Giampietro, Antonella

Isidori, Andrea M

Lauretta, Rosa

Mercuri, Valeria

Poggi, Maurizio

Pontecorvi, Alfredo

Samperi, Irene

Sbardella, Emilia

English

PubMed

INTRODUCTION: Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes. PATIENTS AND METHODS: A retrospective and multicenter study was conducted on 100 SSA-resistant acromegaly patients and treated with Pasireotide Lar (Pasi-Lar), Peg-V in monotherapy (m-Peg-V) or in combination with first gen-SSA (c-Peg-V). RESULTS: Thirty-three patients (33%) were treated with m-Peg-V, 36 (36%) with c-Peg-V and 31 with Pasi-Lar (31%). According to logistic regression, m-Peg-V was chosen in older patients (p = 0.01) and with not-invasive adenomas (p = 0.009), c-Peg-V therapy in younger patients (p = 0.001), with invasive adenomas (p = 0.02), Pasi-Lar was in invasive adenomas (p = 0.01) and in patients partially responsive to first-gen SSA (p = 0.01). At the last follow-up, 68 patients (68%) reached the acromegaly control: 22 with m-Peg-V (32.4%), 23 with c-Peg-V (33.8%) and 23 with Pasi-Lar (33.8%). Patients non-responsive to c-Peg-V had higher IGF-I levels (median 3.2 x ULN, IQR: 1.6, p < 0.001) and required higher Peg-V dosage (median 30 mg/daily IQR: 10, p = 0.002) as compared to responsive patients (median IGF-I x ULN: 2.1 IQR: 1.4; median Peg-V dosage 20 mg/daily IQR: 10). All patients responsive to Pasi-Lar were partially responsive to first gen-SSAs (p = 0.02). CONCLUSION: Our data showed that c-Peg-V and Pasi-Lar are chosen for the treatment of invasive tumors. The partial response to first gen-SSA seems to be the main determinant for the choice of Pasi-Lar and positively predicts the treatment outcome

Isidori, Andrea M.

PubMed Central

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly

Archivio della ricerca- Università di Roma La Sapienza

https://iris.uniroma1.it/bitstream/11573/1652391/3/Chiloiro_Partial-response_2022.pdf

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly

Abstract

Similar works

Full text

Available Versions

PubMed Central

Archivio della ricerca- Università di Roma La Sapienza